WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Stock Ownership - Who owns Diamedica Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Diamedica Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James T. ParsonsDirector2026-01-0210,095$8.42
$85.00kBuy
Randall Michael GiuffreDirector2026-01-026,175$8.42
$51.99kBuy
Charles Pauling SembaDirector2026-01-023,355$8.42
$28.25kBuy
Jan Stahlberg10% Owner2025-11-2573,099$8.58
$626.82kBuy
Jan Stahlberg10% Owner2025-11-2440,253$7.89
$317.72kBuy
James T. ParsonsDirector2025-11-2112,000$2.20
$26.40kBuy
Jan Stahlberg10% Owner2025-11-21208,872$7.41
$1.55MBuy
Jan Stahlberg10% Owner2025-11-20128,426$7.41
$951.25kBuy
Jan Stahlberg10% Owner2025-11-19240,352$7.21
$1.73MBuy
Jan Stahlberg10% Owner2025-11-18182,882$6.75
$1.23MBuy

1 of 3

DMAC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DMAC insiders and whales buy or sell their stock.

DMAC Shareholders

What type of owners hold Diamedica Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Jan Stahlberg29.94%15,590,207$130.96MInsider
Koch Thomas Von26.67%13,887,297$116.65MInsider
Richard Jacinto Ii9.52%4,958,823$41.65MInsider
Cooperman Leon G6.28%3,269,761$27.47MInstitution
Blackrock Inc3.22%1,678,139$14.10MInstitution
Millennium Management LLC2.28%1,187,309$9.97MInstitution
Zhenyu Xiao1.93%1,007,100$8.46MInsider
Paragon Associates Paragon Associates II Joint Venture1.68%875,000$7.35MInstitution
Geode Capital Management LLC1.37%711,818$5.98MInstitution
Vanguard Group Inc1.28%664,575$5.58MInstitution

1 of 3

DMAC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DMAC24.49%71.44%Net BuyingNet Buying
TRDA45.50%54.50%Net SellingNet Selling
ALLO67.52%32.48%Net SellingNet Selling
BNTC68.38%8.49%Net BuyingNet Buying
FBRX62.65%37.35%Net BuyingNet Buying
View Top Biotech Stocks

Diamedica Therapeutics Stock Ownership FAQ

Who owns Diamedica Therapeutics?

Diamedica Therapeutics (NASDAQ: DMAC) is owned by 24.49% institutional shareholders, 71.44% Diamedica Therapeutics insiders, and 4.07% retail investors. Jan Stahlberg is the largest individual Diamedica Therapeutics shareholder, owning 15.59M shares representing 29.94% of the company. Jan Stahlberg's Diamedica Therapeutics shares are currently valued at $123.16M.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.